{
  "nctId": "NCT03799328",
  "briefTitle": "Low Dose Multi-OIT for Food Allergy (LoMo)",
  "officialTitle": "Low Dose Multi Allergen Oral Immunotherapy for Food Allergy",
  "protocolDocument": {
    "nctId": "NCT03799328",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2018-11-13",
    "uploadDate": "2018-11-20T18:16",
    "size": 2337963,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT03799328/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "PHASE2"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NA",
  "interventionModel": "SINGLE_GROUP",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 18,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2019-05-23",
    "completionDate": "2025-04-01",
    "primaryCompletionDate": "2022-11-01",
    "firstSubmitDate": "2018-11-20",
    "firstPostDate": "2019-01-10"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Relevant allergy to 2-5 nuts\n* Serum immunoglobulin E (IgE) \\>0.35 kilounits/L (kU/L) (determined by UniCAP within the past 12 months) and/or a SPT to nut \\>3 mm compared to control\n* Positive oral food challenge (OFC) to less than 300mg of a nut in the nut mix at baseline (cumulative 444mg).\n\nExclusion Criteria:\n\n* History of frequent or repeated, severe or life-threatening episodes of anaphylactic shock\n* use of omalizumab or other non-traditional forms of allergen immunomodulatory therapy (not including corticosteroids) or biologic therapy in the 12 months prior to study entry\n* history of eosinophilic gastrointestinal disease, uncontrolled asthma as defined by Global Initiative for Asthma (GINA)\n* use of beta-blockers(oral)\n* use of angiotensin-converting enzyme inhibitors (ACE)\n* fails to tolerate 4mg of peanut after the first desensitization day\n* Other significant medical conditions that in the opinion of the investigator prevent participation in the study,\n* Previous intubation due to allergies or asthma,\n* Symptomatic atopic dermatitis or chronic urticaria which may interfere with ability to evaluate oral immunotherapy and /or requiring daily medication including antihistamines,\n* Patients with problems related to compliance or following study instructions, Inability to come to hospital every for dose escalation\n* Pregnancy\n* Non-fluency in English because participants may need to communicate with us after hours and be able to describe symptoms and concerns and follow instructions to treat anaphylaxis",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "6 Months",
    "maximumAge": "15 Years",
    "stdAges": [
      "CHILD"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Desensitization to allergic food as assessed by change in maximum tolerated dose in a dichotomous manner",
        "description": "Change in how much nuts the participant can eat without an allergic reaction after the low dose OIT assessed as dichotomous did the participant reach 5 times the baseline eliciting dose",
        "timeFrame": "month 0, month 18"
      },
      {
        "measure": "Immunological change in IgG4",
        "description": "Change in allergen specific immunoglobulin G4 (IgG4) from baseline to end",
        "timeFrame": "month 0, month 18"
      }
    ],
    "secondary": [
      {
        "measure": "Desensitization to allergic food as assessed by change in maximum tolerated dose on a linear scale",
        "description": "A continuous variable amount tolerated at baseline vs at end",
        "timeFrame": "month 0, month 18"
      },
      {
        "measure": "Immunological change in IgG4",
        "description": "Change in IgG4 from measures from historical data to 18 month of study. Some patients will have historical IgG4 values to compare",
        "timeFrame": "pre-study, month 18"
      },
      {
        "measure": "Desensitization to allergic food as assessed by maximum tolerated dose",
        "description": "Did they reach 300mg (cumulative) on the 18 month exit oral food challenge",
        "timeFrame": "month 18"
      },
      {
        "measure": "Desensitization to allergic food as assessed by maximum tolerated dose",
        "description": "Did they reach 140mg (cumulative) on the 18 month exit oral food challenge",
        "timeFrame": "month 0, month 18"
      }
    ],
    "other": [
      {
        "measure": "Feasibility analysis as assessed by can the patients achieve the maintenance dosing of the allergen mix for OIT",
        "description": "Proportion who achieve maintenance doses of their allergen mix (descriptive)",
        "timeFrame": "month 18"
      },
      {
        "measure": "Feasibility analysis as assessed by drop-out rate",
        "description": "Proportion who drop-out of the study (descriptive)",
        "timeFrame": "month 18"
      },
      {
        "measure": "Incidence of Treatment-Emergent Adverse Events: Safety analysis as assessed by use of epinephrine",
        "description": "Administration of epinephrine; (descriptive);",
        "timeFrame": "month 18"
      },
      {
        "measure": "Quality of life scale",
        "description": "Change in quality of life at 18m of children compared to baseline assessment (using validated questionnaire: Food allergy quality of life questionnaires (FAQLQ) FAQLQ Parental form (PF) for ages 0-12 OR the FAQLQ-teenager form (TF) using total score. The FAQLQ total and domain scores range from 1-7 with higher scores indicative of worse health related quality of life with the total score being the average of the domain scores. The domains include Emotional Impact, Social and Dietary Restrictions, Food Anxiety, Allergen Avoidance, and Risk of Accidental Exposure.",
        "timeFrame": "month 0, month 18"
      },
      {
        "measure": "Change in allergen specific IgE, and components",
        "description": "Change in allergen specific IgE, and components via microarray",
        "timeFrame": "month 0, month 18"
      },
      {
        "measure": "Basophil activation test",
        "description": "Basophil activation test",
        "timeFrame": "month 0, month 18"
      },
      {
        "measure": "Skin prick test (SPT) reactivity to the individual nut extracts",
        "description": "The size of the skin prick test will be compared",
        "timeFrame": "month 0, month 18"
      },
      {
        "measure": "High content functional immune profiling via mass cytometry and single cell sorting",
        "description": "Compare the change in the immune pattern",
        "timeFrame": "pre-study, month 18"
      },
      {
        "measure": "Number of participants with treatment related adverse effects",
        "description": "Diaries will be analyzed for allergic symptoms and tabulated",
        "timeFrame": "month 0, month 18"
      }
    ]
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 2,
      "secondaryCount": 4,
      "otherCount": 9,
      "totalCount": 15
    },
    "studyDesign": {
      "phases": [
        "PHASE2"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "SINGLE_GROUP"
    },
    "overallComplexityScore": 62,
    "complexityCategory": "Complex"
  },
  "collectionDate": "2025-09-22T02:30:48.061Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}